Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493518 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01493518 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 6 participants.
The verdict
NCT01493518, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to study the safety, tolerability and immunogenicity of AMG 557 following multiple subcutaneous dose administration in adults with moderate to severe psoriasis.
Interventions
- DRUG AMG 557 or PLACEBO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493518
The ClinicalTrials.gov registry entry for NCT01493518 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 557 or PLACEBO is the first listed.
NCT01493518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01493518 about?
NCT01493518 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis". The purpose of this study is to study the safety, tolerability and immunogenicity of AMG 557 following multiple subcutaneous dose administration in adults with moderate to severe psoriasis.
What is the current status of trial NCT01493518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01493518?
The interventions under investigation include: AMG 557 or PLACEBO (DRUG).
Who is sponsoring clinical trial NCT01493518?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.